| Autor: |
Reinus, John F., Persky, Seth, Burkiewicz, Jill S., Quan, David, Bass, Nathan M., Davern, Timothy J., Reinus, J F, Persky, S, Burkiewicz, J S, Quan, D, Bass, N M, Davern, T J |
| Předmět: |
|
| Zdroj: |
Annals of Internal Medicine; 12/19/2000, Vol. 133 Issue 12, p964-968, 5p |
| Abstrakt: |
Background: In registration trials, zafirlukast, an asthma medication, caused asymptomatic elevated aminotransferase levels in up to 5% of participants. Until now, however, no cases of severe hepatitis attributed to zafirlukast have been reported.Objective: To report the clinical characteristics of three patients with severe hepatitis due to zafirlukast.Design: Case report.Setting: One community hospital and two university hospitals.Patients: Three middle-aged women taking zafirlukast, 20 mg twice per day.Intervention: Discontinuation of zafirlukast therapy in three patients, steroid therapy in two patients, and orthotopic liver transplantation in one patient.Measurements: Serum aminotransferase and bilirubin levels, standard blood tests for causes of hepatitis other than drug toxicity, and liver biopsy in two patients.Results: Patient 1 recovered spontaneously, had a severe relapse after inadvertent rechallenge with the medication, and ultimately made a complete recovery. Patient 2 developed subfulminant hepatic failure and required liver transplantation. Patient 3 developed severe hepatitis that improved after treatment with corticosteroids. Liver tissue was available from two patients and showed histologic changes commonly associated with drug reactions.Conclusion: Patients receiving zafirlukast may develop severe liver injury and should be observed for signs and symptoms of hepatitis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
